Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:ALXO NASDAQ:EXOZ NASDAQ:IKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.46-7.7%$2.67$1.65▼$4.00$249.85M1.59305,302 shs295,085 shsALXOALX Oncology$2.13-3.4%$1.78$0.41▼$2.66$285.95M0.441.04 million shs298,833 shsEXOZeXoZymes$8.46+0.4%$9.21$6.33▼$18.40$71.65M2.664,908 shs11,529 shsIKTInhibikase Therapeutics$1.95+0.8%$1.79$1.33▼$2.26$256.80M0.931.34 million shs872,504 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+4.52%+6.40%0.00%-3.27%+32.34%ALXOALX Oncology+7.84%+34.97%+15.79%+9.73%+442.14%EXOZeXoZymes+6.79%+2.93%-12.11%+12.12%-18.96%IKTInhibikase Therapeutics+1.31%+4.89%+10.29%+14.88%+192,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.46-7.7%$2.67$1.65▼$4.00$249.85M1.59305,302 shs295,085 shsALXOALX Oncology$2.13-3.4%$1.78$0.41▼$2.66$285.95M0.441.04 million shs298,833 shsEXOZeXoZymes$8.46+0.4%$9.21$6.33▼$18.40$71.65M2.664,908 shs11,529 shsIKTInhibikase Therapeutics$1.95+0.8%$1.79$1.33▼$2.26$256.80M0.931.34 million shs872,504 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune+4.52%+6.40%0.00%-3.27%+32.34%ALXOALX Oncology+7.84%+34.97%+15.79%+9.73%+442.14%EXOZeXoZymes+6.79%+2.93%-12.11%+12.12%-18.96%IKTInhibikase Therapeutics+1.31%+4.89%+10.29%+14.88%+192,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.25Hold$7.50205.50% UpsideALXOALX Oncology 2.67Moderate Buy$4.60116.47% UpsideEXOZeXoZymes 1.00SellN/AN/AIKTInhibikase Therapeutics 3.11Buy$5.40177.63% UpsideCurrent Analyst Ratings BreakdownLatest EXOZ, ACIU, IKT, and ALXO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026ALXOALX Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026IKTInhibikase Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.005/29/2026EXOZeXoZymes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$4.31M57.97N/AN/A$0.54 per share4.55ALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/AEXOZeXoZymes$70K1,024.26N/AN/A$0.40 per share21.14IKTInhibikase TherapeuticsN/AN/AN/AN/A$2.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.44N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)ALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)EXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AIKTInhibikase Therapeutics-$48.26M-$0.43N/AN/AN/AN/A-41.31%-38.98%N/ALatest EXOZ, ACIU, IKT, and ALXO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A5/12/2026Q1 2026IKTInhibikase Therapeutics-$0.10-$0.10N/A-$0.10N/AN/A5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 million3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AALXOALX OncologyN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02ALXOALX Oncology0.027.217.21EXOZeXoZymes0.031.321.32IKTInhibikase TherapeuticsN/A30.1430.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%ALXOALX Oncology97.97%EXOZeXoZymesN/AIKTInhibikase Therapeutics3.81%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%ALXOALX Oncology21.00%EXOZeXoZymes72.41%IKTInhibikase Therapeutics7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableALXOALX Oncology40134.56 million106.31 millionOptionableEXOZeXoZymes298.48 million2.34 millionN/AIKTInhibikase Therapeutics6132.03 million122.66 millionN/AEXOZ, ACIU, IKT, and ALXO HeadlinesRecent News About These CompaniesBank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)June 29 at 12:30 PM | theglobeandmail.comAnalysts Set Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Price Target at $5.40June 25, 2026 | americanbankingnews.comLifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)May 17, 2026 | theglobeandmail.comAnalyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk FactorsMay 14, 2026 | tipranks.comInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityMay 12, 2026 | globenewswire.comInhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial HypertensionMay 12, 2026 | tipranks.comInhibikase enrolls first patient in phase 3 PAH trialApril 14, 2026 | msn.comInhibikase grants stock options to five new employeesApril 8, 2026 | msn.comInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial HypertensionApril 7, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)April 6, 2026 | theglobeandmail.comInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.76%March 28, 2026 | aaii.comAInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent ActivityMarch 26, 2026 | globenewswire.comInhibikase Therapeutics Inc Ordinary Shares IKTMarch 14, 2026 | morningstar.comMAnalysts Are Bullish on These Healthcare Stocks: Inhibikase Therapeutics (IKT), MoonLake Immunotherapeutics (MLTX)February 24, 2026 | theglobeandmail.comB of A Securities Initiates Coverage of Inhibikase Therapeutics (IKT) with Buy RecommendationJanuary 22, 2026 | msn.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.67%December 26, 2025 | aaii.comAInhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71December 21, 2025 | msn.comInhibikase Updates ATM Equity Program to Raise CapitalDecember 19, 2025 | tipranks.comInhibikase Therapeutics initiated with an overweight at Cantor FitzgeraldDecember 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEXOZ, ACIU, IKT, and ALXO Company DescriptionsAC Immune NASDAQ:ACIU$2.46 -0.21 (-7.71%) As of 12:36 PM Eastern This is a fair market value price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.ALX Oncology NASDAQ:ALXO$2.13 -0.07 (-2.95%) As of 12:36 PM Eastern This is a fair market value price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.eXoZymes NASDAQ:EXOZ$8.03 -0.39 (-4.63%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Inhibikase Therapeutics NASDAQ:IKT$1.94 +0.01 (+0.26%) As of 12:36 PM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Wall Street Still Sees Massive Upside for AeroVironment Stock Manchester United’s Stock Rally Faces a Test Beyond Old Trafford Why AppLovin’s CEO Is Selling While Quantum Insiders Are Buying Volkswagen’s 16-Year Low Masks a Massive Margin Engine Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat Overclocking Qualcomm: Rewiring the AI Compute Market SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
